The National Agency for Food and Drug Administration and Control (NAFDAC) has officially blacklisted MD Life Sciences Ltd, situated at Water Rock Greens, 21 Old Airport Road, Emene Industrial Layout, Enugu State. This sanction arises from serious regulatory breaches: engaging unauthorized third-party manufacturers without NAFDAC approval and distributing products without stated active ingredients.
MD Life Sciences Ltd operates from Emene Industrial Layout in Enugu State. While it presents itself as a pharmaceutical marketer, the company procured manufacturing services from other entities—notably Impact Pharmaceutical Ltd and Ecomed Pharma Ltd—without submitting dossiers or securing manufacturing site inspections by NAFDAC.
NAFDAC’s investigation uncovered two core infringements:
- Contract manufacturing without agency oversight
MD Life Sciences Ltd subcontracted production of its branded pharmaceuticals to Impact Pharmaceutical Ltd, Ecomed Pharma Ltd, and similar outfits, bypassing mandatory product registration and Good Manufacturing Practice (GMP) inspections.
- Marketing products lacking active ingredients
The company circulated counterfeit antimalarial formulations—such as Paludex (Artemether/Lumefantrine) dry powder for suspension, Paudex tablets, and Ciprofit (Ciprofloxacine) tablets—found to contain none of the labelled active compounds, rendering them therapeutically ineffective.
NAFDAC’s blacklisting mechanism serves to shield public health by:
- Prohibiting the sale, distribution, or use of all products associated with the erring firm.
- Alerting healthcare providers and consumers to potential safety hazards.
For MD Life Sciences Ltd, blacklisting entails:
- Immediate cessation of all product marketing and importation activities.
- Potential prosecution for offenses under the NAFDAC laws and regulations.
All NAFDAC zonal directors and state coordinators have been directed to carry out surveillance and mop up the substandard/falsified products within their zones and states.
NAFDAC implores distributors, suppliers, wholesalers, healthcare providers, and patients to exercise caution and vigilance within the supply chain to avoid distribution, sale, administration, and use of the products. All medical products must be obtained from genuinely authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
If you have any of the products mentioned above, please stop selling or using them immediately and submit your stock to the nearest NAFDAC office. If you or someone you know has used any of these products and experienced adverse reactions or events, we strongly recommend seeking immediate medical advice from a qualified healthcare professional.
Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of the medicinal product to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med-safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
Thank you.
Prof. Mojisola Christianah Adeyeye FAS
Director General
lvinar dapibus leo.
